Efficacy Data of SNT-317 Presented

Santhera tests in merosin deficient mouse models with omigapil showed decreased apoptosis (programmed cell death) and improved survival outcome. Co-administration with mini-agrin had additive beneficial effects. Santhera presents efficacy data of SNT-317 (omigapil) in CMD. Santhera pharmaceutical and partner TREAT-NMD, announced positive preclinical data. Omigapil is an oral compound, released by Novartis, with European Orphan Drug Status for treatment of both merosin deficient CMD and Ullrich CMD.



This entry was posted in Research News. Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Congenital Muscular Dystrophy

    A group of diseases causing muscle weakness at birth. Several defined genetic mutations cause muscles to break down faster than they can repair or grow. A child with CMD may have various neurological or physical impairments. Some children never gain the ability to walk, while others lose the ability as they grow older. Learn more...

  • Register Now!